TY - JOUR T1 - Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2020-218258 SP - annrheumdis-2020-218258 AU - Andrea Hermina Györfi AU - Markus Kopp AU - Matthias May AU - Marcel Vetter AU - Michael Uder AU - Andreas E Kremer AU - Georg Schett AU - Thomas Harrer AU - Jörg H W Distler Y1 - 2020/06/30 UR - http://ard.bmj.com/content/early/2020/06/30/annrheumdis-2020-218258.abstract N2 - The COVID-19 pandemic represents a challenge for rheumatologists: how activity of rheumatological diseases or disease-modifying therapies may affect the outcome of SARS-CoV-2 infection is only beginning to be understood. Gianfrancesco et al provided important insights in this regard by evaluating the hospitalisation rate of 600 patients with rheumatological diseases from 40 different countries.1 They found that glucocorticoid treatment in doses equivalent with prednisolone 10 mg/day or higher was associated with an increased hospitalisation rate.Here, we describe the case of a 50-year-old man who was diagnosed with Löfgren syndrome in January 2019 presenting with cough, bilateral ankle joint swelling and mediastinal lymphadenopathy. ACE (37.3 U/L, normal range <21.4) and soluble IL-2 receptor (1445 U/mL, normal range <710) were elevated in the serum. The patient was treated with glucocorticoids until October 2019 with complete remission of clinical symptoms and normalisation of laboratory parameters.On 12 March 2020, the patient had contact with a person who later tested positive for SARS-CoV-2 RNA. One week after the SARS-CoV-2 contact, the patient developed fever (38°C) and dry cough suggesting SARS-CoV-2 infection. In addition, he developed pain in the ankles during night … ER -